China NMPA Drug Inspection - Shandong Ruian Pharmaceutical Co., Ltd. commissioned Chifeng Wanzhe Pharmaceutical Co., Ltd. - Tacrolimus ointment
China NMPA drug inspection for Shandong Ruian Pharmaceutical Co., Ltd. commissioned Chifeng Wanzhe Pharmaceutical Co., Ltd. published August 18, 2023. Drug: Tacrolimus ointment. On August 18, 2023, China’s National Medical Products Administration (NMPA) released Announcement No. 36, detailing four
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Shandong Ruian Pharmaceutical Co., Ltd. commissioned Chifeng Wanzhe Pharmaceutical Co., Ltd. published August 18, 2023. Drug: Tacrolimus ointment. On August 18, 2023, China’s National Medical Products Administration (NMPA) released Announcement No. 36, detailing four
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox